In a study of NGS testing rates of genomic biomarkers in NSCLC patients treated at community sites, only 15% of the 814 patients underwent NGS testing for MET, a sharp decline compared to EGFR (69%) or ALK (65%) testing rates [67]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.